Summary
Current concepts and future aspects of pharmacological interventions in the treatment of coronary heart disease have been compiled. Especially new insights in the pathophysiology of coronary heart disease e. g. the dynamic pathology of coronary atherosclerosis, possible role of endothelin in vasospasm, as well as new pharmacodynamic and pharmacokinetic aspects of organic nitrates are discussed. Also the role of sympathetic nervous system as a pivotal question in pathophysiology and clinical pharmacology in the treatment of angina pectoris has been considered.
Similar content being viewed by others
References
Prinzmetal M, Kennamer R, Merliss R, Wada T, Bor N (1959) Angina pectoris: I. A variant form of angina pectoris. Preliminary report. Am J Med 27: 375–388
Gensini GG, DiGiorgi S, Murad-Netto S, Black A (1962) Arteriographic demonstration of coronary artery spasm and its release after use of vasodilator in a case of angina pectoris and in the experimental animal. Angiology 13:550–553
Brown BG (1981) Coronary vasospasm: observation lenking the clinical spectrum of ischemic heart disease to the dynamic pathology of coronary atherosclerosis. Clin Comment Arch Intern Med 141:716–722
Yanagisawa M, Kurihara H, Kimura S et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411–415
Dominiak P, Schulz W, Delius W, Kober G, Grobecker H (1981) Catecholamine in patients with coronary heart disease. In: Delius W, Gerlach E, Grobecker H, Kübler W (eds) Catecholamines in the heart. Recent advances in experimental and clinical research. Springer, Berlin Heidelberg New York, pp 223–235
Penttilä O, Merikallio E, Klinge E, Siltanen P, Pispa J, Kybsola K (1981) Myocardial catecholamines and biosynthetic enzymes in various heart diseases of man. In: Delius W, Gerlach E, Grobecker H, Kübler W (eds) Catecholamines and the heart. Springer, Berlin Heidelberg New York, pp 211–222
Cohen JN (1984) Unloading the heart in congestive heart failure. Am J Med 77: 67–70
Kupper W (1987) Klinische Bedeutung der stummen Myokardieschämie und ihre therapeutischen Konsequenzen. In: Grobecker H (ed) Chronische Nitrattherapie. Verlag für angewandte Wissenschaften, Munich, pp 103–116
Palmer RMJ, Ferrige AG, Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524–526
Mackenzie JE, Parratt JR (1977) Comparative effects of glyceryl trinitrate on venous and arterial smooth muscle in vitro; relevance to angioanginal activity. Br J Pharmacol 60: 155–160
Sharma B, Hodges M, Asinger RW, Goodwin JF, Francis GS (1980) Left ventricular function during spontaneous angina pectoris: effect of sublingual nitroglycerin. Am J Cardiol 46: 34–41
Klein RC, Grehl TM, Sengert KB, Mason DT (1981) Evaluation of the effects of systemic nitroglycerin on perfusion of ischaemic myocardium in coronary heart disease assessed intraoperatively by antegrade blood flow through intact saphenous vein bypass grafts. Am Heart J 101: 292–299
Kober G, Großmann R, Schulz W, Kaltenbach M (1981) Durchmesseränderungen der kleinen arteriellen und venösen Lungengefäße unter Nitroglycerin. Z Kardiol 70: 547–554
Abshagen U (1985) Organic nitrates. In: Abshagen U (ed) Clinical pharmacology of antianginal drugs. Springer, Berlin Heidelberg New York, pp 287–364
Mannebach H, Ohlmeier H, Möllendorff E, Gleichmann U, Abshagen U (1981) Steady-state-Kinetic von Isosorbid-5-Mononitrat bei Patienten mit koronarer Herzkrankheit. Med Welt 32: 517–520
Reifart N, Reifart F, Kaltenbach M, Bussmann W-D (1981) Vergleich der antianginösen Wirksamkeit und Wirkdauer von oral verabreichtem Isosorbiddinitrat (ISDN), Isosorbid-2-Mononitrat (IS-2-MN) Lind Isosorbid-5-Mononitrat (IS-5-MN). Med Welt 32: 524–526
Needlemann P (1970) Tolerance to the vascular effects of glyceryl trinitrate. J Pharmacol Exp Ther 171: 98–102
Parker JO, Fung H-L (1984) Transdermal nitroglycerin in angina pectoris. Am J Cardiol 54: 471–476
Ignarro LJ, Lippton H, Edwards JC et al (1981) Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 218: 739–749
Müller K (1987) In: Grobecker H (ed) Chronische Nitrattherapie. Verlag für angewandte Wissenschaften, Munich, pp 59–72
Fleckenstein A (1983) Calcium antagonism in heart and smooth muscle. Wiley, New York
Grobecker H (1985) Über das sympatho-adrenale System. Implikationen zur Pathogenese, Diagnose und Therapie des hohen Blutdrucks. In: Dengler HJ, Palm D (eds) Hochdrucktherapie-Mechanismen und Konzepte. Schattauer, Stuttgart New York, pp 19–27
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grobecker, H. Pharmacology and clinical pharmacology of organic nitrates. Eur J Clin Pharmacol 38 (Suppl 1), S3–S7 (1990). https://doi.org/10.1007/BF01417558
Issue Date:
DOI: https://doi.org/10.1007/BF01417558